Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...
Denali Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...
Denali Gains 26.6% in a Year: How Should You Play the Stock?
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
Denali Therapeutics’ (DNLI) Outperform Rating Reiterated at William Blair
William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...
BioSpace1d
FDA Tacks Boxed Warning on Teva’s Copaxone, Other MS Drugs
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...
MarketWatch6d
Denali Therapeutics Inc.
Copyright © 2025 MarketWatch, Inc. All rights reserved.
pharmaphorum4d
Biogen buys into Denali’s amyloid beta programme
By linking therapeutics to engineered molecules that bind to transport receptors at the BBB, concentrations of the drugs can be increased 10- to 30-fold, according to Denali. Applying the approach ...
Forbes3d
Trump Renames Denali To Mount McKinley—Here’s What To Know
President Donald Trump signed an executive order Monday renaming Denali—the highest peak in North America—to Mount McKinley, the Alaska mountain’s name prior to 2015, a move he has suggested ...